Connor, Clark & Lunn Investment Management Ltd. Seres Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$3.5 - $7.2 $59,776 - $122,968	17,079 Added 32.22%	70,085 $450,000
Q2 2022 Aug 05, 2022	SELL	$2.7 - $7.62 $332,286 - $937,785	-123,069 Reduced 69.9%	53,006 $182,000
Q1 2022 May 12, 2022	SELL	$6.3 - $8.84 $263,925 - $370,334	-41,893 Reduced 19.22%	176,075 $1.25 Million
Q4 2021 Feb 10, 2022	BUY	$6.02 - $11.43 $1.02 Million - $1.94 Million	169,987 Added 354.28%	217,968 $1.82 Million
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $89,129 - $368,922	16,324 Added 51.57%	47,981 $334,000

Q2 2021 Aug 12, 2021	BUY	$18.46 - $24.36 $584,388 - $771,164	31,657 New	31,657 $755,000
Q2 2019 Aug 07, 2019	SELL	$2.28 - $7.35 $38,988 - $125,685	-17,100 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$4.83 - $7.21 $2,898 - $4,326	600 Added 3.64%	17,100 $117,000
Q4 2018 Feb 12, 2019	BUY	$4.52 - $8.88 $2,260 - $4,440	500 Added 3.13%	16,500 $75,000
Q3 2018 Nov 13, 2018	BUY	$7.33 - $9.23 $17,592 - $22,152	2,400 Added 17.65%	16,000 $121,000
Q2 2018 Aug 02, 2018	BUY	$6.91 - $9.55 $93,976 - $129,880	13,600 New	13,600 $117,000

Others Institutions Holding MCRB

# of Institutions

100

Shares Held

62.7M

Call Options Held

36.9K

Put Options Held

476K

Flagship Pioneering Inc. Cambridge, MA

23.1M
Shares

$16.6 Million
1.17% of portfolio
Black Rock Inc. New York, NY

6.83M
Shares

$4.91 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.73M
Shares

$4.85 Million
0.0% of portfolio
Hudson Bay Capital Management LP Greenwich, CT

5.43M
Shares

$3.91 Million
0.03% of portfolio
Geode Capital Management, LLC Boston, MA

2.13M
Shares

$1.54 Million
0.0% of portfolio

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account